LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Crane, Philippa (2016)
Languages: English
Types: Doctoral thesis
Subjects: R852
The organisation of drug development has radically changed in the last 40 years due to changes in the scientific knowledge base and the availability of new forms of finance. Stimulated by breakthroughs in biotechnology, new investment has facilitated changes to the strategies and structure of the industry. Furthermore, scientific advances have provided greater understanding of disease, drug targets and disease-drug interactions, particularly in oncology. Yet new ways of organising innovation bring new challenges. This thesis provides evidence to inform new policies and business models by assessing the non-technical conditions associated with the success and failure of drug development projects. The thesis presents an integrative theoretical framework that supports a multi-dimensional analysis of the network, organisation and individuals involved in drug projects. This approach is applied to case studies of 11 development projects for rare cancer drugs involving UK organisations. These cases are then compared and contrasted through a descriptive multi-case analysis and a Qualitative Comparative Analysis.\ud \ud The findings contribute towards an understanding of the environmental conditions for the successful development of drugs. Firstly, the concept of project drag is introduced, to draw attention to the accumulation of issues during development that can cause projects lose momentum and lead to termination. The organisational environment around firms is found to be key; common disruptions are identified, particularly within small firms which are more vulnerable to industrial dynamics than larger organisations. This thesis also highlights mechanisms that can mediate adverse conditions; key individuals, their networks, power and consistent enthusiasm for projects can mediate project drag. The thesis also makes a methodological contribution in the formation and operationalisation of an integrative framework for project evaluation which provides a foundation for further research in this area. The thesis is concluded with policy recommendations of pathways that contribute towards the successful development of drug projects.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • KNOX, R. J., FRIEDLOS, F. & BOLAND, M. P. 1993. The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT). Cancer Metastasis Rev, 12, 195-212.
    • KNOX, R. J., FRIEDLOS, F., JARMAN, M. & ROBERTS, J. J. 1988b. A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2- nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells. Biochem Pharmacol, 37, 4661-9.
    • KNOX, R. J., FRIEDLOS, F., MARCHBANK, T. & ROBERTS, J. J. 1991. Bioactivation of CB 1954: reaction of the active 4-hydroxylamino derivative with thioesters to form the ultimate DNA-DNA interstrand crosslinking species. Biochem Pharmacol, 42, 1691-7.
    • KNOX, R. J., JENKINS, T. C., HOBBS, S. M., CHEN, S., MELTON, R. G. & BURKE, P. J. 2000. Bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by human NAD(P)H quinone oxidoreductase 2: a novel co-substrate-mediated antitumor prodrug therapy. Cancer Res, 60, 4179-86.
    • KOCH, L. 2006. Past Futures: On the Conceptual History of Eugenics-a Social Technology of the Past. Technology Analysis & Strategic Management, 18, 329- 344.
    • KOENIG, R. 2006. The Legacy of Great Science: The Work of Nobel Laeureate Gertrude Elion Lives On. . The Oncology, 11, 961-965.
    • KOGLIN, O. H. 2000. 'Miracle' pill takes away all traces of leukemia: 30% of patients in Oregon study are now cancer-free: Cancer breakthrough. Edmonton Journal, December 3, 2000.
    • KOGUT, B. & ZANDER, U. 1992. Knowlegde of the Firm, Combinative Capabiities, and the Replication of Technology. Organization Science, 3, 383-397.
    • KOHLER, G. & MILSTEIN, C. 1975. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 256, 495-497.
    • KOIZUMI, W., AIBA, K., SASAKI, T., SATO, A. & HORIKOSHI, N. 2003. Phase I doseescalation trial of ZD9331 in Japanese patients with refractory, solid malignancies. Anti-Cancer Drugs, 14, S1-S5.
    • KOLA, I. & LANDIS, J. 2004. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov, 3, 711-716.
    • KONRAD, K. 2006. The social dynamics of expectations: The interaction of collective and actor-specific expectations on electronic commerce and interactive television. Technology Analysis & Strategic Management, 18, 429-444.
    • KREITMAN, R. J., MARGULIES, I., STETLER-STEVENSON, M., WANG, Q. C., FITZGERALD, D. J. & PASTAN, I. 2000. Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias. Clin Cancer Res, 6, 1476-87.
    • KREITMAN, R. J. & PASTAN, I. 2006. BL22 and lymphoid malignancies. Best Pract Res Clin Haematol, 19, 685-99.
    • KREITMAN, R. J. & PASTAN, I. 2011. Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res, 17, 6398-405.
    • KREITMAN, R. J., SQUIRES, D. R., STETLER-STEVENSON, M., NOEL, P., FITZGERALD, D. J. P., WILSON, W. H. & PASTAN, I. 2005a. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-Cell malignancies. Journal of Clinical Oncology, 23, 6719-6729.
    • KREITMAN, R. J., STETLER-STEVENSON, M., MARGULIES, I., NOEL, P., FITZGERALD, D. J. P., WILSON, W. H. & PASTAN, I. 2009. Phase II Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With Hairy Cell Leukemia. Journal of Clinical Oncology, 27, 2983-2990.
    • KREITMAN, R. J., WANG, Q.-C., FITZGERALD, D. J. P. & PASTAN, I. 1999. Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys. International Journal of Cancer, 81, 148-155.
    • KREITMAN, R. J., WILSON, W. H., BERGERON, K., RAGGIO, M., STETLERSTEVENSON, M., FITZGERALD, D. J. & PASTAN, I. 2001a. Efficacy of the antiCD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med, 345, 241-7.
    • KREITMAN, R. J., WILSON, W. H., NOEL, P., STETLER-STEVENSON, M., RAFFELD, M., SORBARA, L., SQUIRES, D., O'HAGAN, D., ZANCAN, M., BERGERON, K., FITZGERALD, D. J. & PASTAN, I. 2001b. Complete remission of chemoresistant hairy cell leukemia with recombinant anti-CD22 immunotoxin BL22, relapse, and status of minimal residual disease in the blood and bone marrow. Blood, 98, 635A-636A.
    • KREITMAN, R. J., WILSON, W. H., STETLER-STEVENSON, M., FITZGERALD, D. J. & PASTAN, I. 2005b. Recombinant anti-CD22 immunotoxin BL22 induces durable complete remissions in phase I and II trials of patients with chemoresistant hairy cell leukemia. Clinical Cancer Research, 11, 9120S-9121S.
    • KREITMAN, R. J., WILSON, W. H., STETLER-STEVENSON, M., NOEL, P., FITZGERALD, D. J. & PASTAN, I. 2008. Pharmacokinetics of recombinant immunotoxin BL22 during phase II testing in chemo-resistant hairy cell leukemia. Journal of Clinical Oncology, 26.
    • KREITMAN, R. J., WILSON, W. H., STETLER-STEVENSON, M., NOEL, P. & PASTAN, I. 2004. Long term follow-up of BL22 in cladribine-resistant hairy cell leukemia. Journal of Clinical Oncology, 22, 588S-588S.
    • KRENITSKY, T., KOSZALKA, G. W., TUTTLE, J. V., RIDEOUT, J. L. & ELION, G. B. 1981. An enzymatic synthesis of purine D-arabinonucleosides. Carbohydrate Research, 97, 139-146.
    • KRENITSKY, T. A., AVERETT, D. R. & KOSZALKA, G. W. 1998a. Tumor treatment with arabinofuranosyl purine derivatives. Google Patents.
    • KRENITSKY, T. A., AVERETT, D. R., KOSZALKA, G. W. & WOLBERG, G. 1996a. Method for treating T-cell lymphoblastic leukemia with ara-G nucleoside derivatives. USA patent application.
    • KRENITSKY, T. A., AVERETT, D. R., KOSZALKA, G. W. & WOLBERG, G. 1996b. Method for treating T-cell lymphoblastic leukemia with ara-G nucleoside derivatives. Google Patents.
    • KRENITSKY, T. A., AVERETT, D. R., KOSZALKA, G. W. & WOLBERG, G. 1998b. Anticarcinogenic agents and antitumor agents. Google Patents.
    • KRENITSKY, T. A. & PORTER, D. J. T. 1995. 9-β-D-arabinofuranasyl-2-amino-6- methaoxy-9H-purine. Google Patents.
    • KRENITSKY, T. A. & PORTER, D. J. T. 1996. 5'-O-propionyl and 5'-O-butyryl esters of 2-amino-6-methoxy-9-(β-D-arabinofuranosyl)-9H-purine. Google Patents.
    • KS BIOMEDIX HOLDINGS PLC. 1995. Initial Public Offering onto the Alternative Investment Market of the London Stock Exchange - Prospectus.
    • KS BIOMEDIX HOLDINGS PLC. 2000. KS Biomedix Holdings Plc Preliminary Results for the Year Ended 31st May 2000. September 9, 2000.
    • KS BIOMEDIX HOLDINGS PLC. 2001a. FDA Grants Fast Track Status to KS Biomedix's TransMID-107 (TM) for the Treatment of Brain Cancer. Press Release, August 6, 2001.
    • KS BIOMEDIX HOLDINGS PLC. 2001b. FDA Grants Orphan Drug Status to KS BIomedix's TransMID-107 for the Treatment of Malignant Tumours of the Central Nervous System. December 11, 2001.
    • KS BIOMEDIX HOLDINGS PLC. 2001c. KS Biomedix says FDA grants Orphan Drug Status to TransMID-107 oncology drug. December 11, 2001.
    • KS BIOMEDIX HOLDINGS PLC. 2001d. Preliminary Results for the Year Ended 31st May 2001. September 24, 2001.
    • KS BIOMEDIX HOLDINGS PLC. 2002a. European Commission Grants Orphan Designation to KS Biomedix's TransMID-107 for the Treatment of Glioma. March 22, 2002.
    • KS BIOMEDIX HOLDINGS PLC. 2002b. KS Biomedix licences TransMID brain cancer product to Nycomed. September 17, 2002
    • KS BIOMEDIX HOLDINGS PLC. 2002c. KS Biomedix Licenses TransMID(TM) Brain Cancer Product to Sosei in $25m Japanese Deal. May 27, 2002
    • KS BIOMEDIX HOLDINGS PLC. 2002d. KS Biomedix to Commence Clinical Study of TransMID (TM) in children with brain tumours. May 7, 2002.
    • KS BIOMEDIX HOLDINGS PLC. 2002e. Promising results from KS Biomedix brain cancer drug. Press Release, October 20, 2002.
    • KS BIOMEDIX HOLDINGS PLC. 2003a. K.S. Biomedix Hldgs (KSB.L) Final Results., August 14, 2003
    • KS BIOMEDIX HOLDINGS PLC. 2003b. Preliminary Results For the Year Ended 31 May 2003. August 14, 2003.
    • KS BIOMEDIX HOLDINGS PLC. 2003c. Recommended Offer by Nomura on behalf of Xenova Group plc ("Xenova") for KS Biomedix Holdings Plc. August 14, 2003.
    • KUDOS PHARMACEUTICALS 1999. KuDOS Pharmaceuticals Completes Initial Financing Press Release.
    • KUDOS PHARMACEUTICALS 2002. KuDOS completes major third round of private equity funding. Press Release.
    • KUDOS PHARMACEUTICALS 2003. KuDOS Pharmaceuticals licenses North American rights to AQ4N to Novacea Inc. Press Release.
    • KUDOS PHARMACEUTICALS 2005. Acquisition Of KuDOS Pharmaceuticals Will Enhance AstraZeneca's Ability To Generate Novel Cancer Treatments. In: RELEASE, P. (ed.).
    • KUHN, T., S 1962. The Structure of Scientific Revolutions.
    • KUMAR KAKKAR, A. & DAHIYA, N. 2014. The evolving drug development landscape: from blockbusters to niche busters in the orphan drug space. Drug Dev Res, 75, 231-4.
    • KUMAR, R., KNICK, V. B., RUDOLPH, S. K., JOHNSON, J. H., CROSBY, R. M., CROUTHAMEL, M. C., HOPPER, T. M., MILLER, C. G., HARRINGTON, L. E., ONORI, J. A., MULLIN, R. J., GILMER, T. M., TRUESDALE, A. T., EPPERLY, A. H., BOLOOR, A., STAFFORD, J. A., LUTTRELL, D. K. & CHEUNG, M. 2007. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther, 6, 2012-21.
    • KURTZBERG, J., ERNST, T. J., KEATING, M. J., GANDHI, V., HODGE, J. P., KISOR, D. F., LAGER, J. J., STEPHENS, C., LEVIN, J., KRENITSKY, T., ELION, G. & MITCHELL, B. S. 2005. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. Journal of Clinical Oncology, 23, 3396-3403.
    • KURTZBERG, J., KEATING, M., MOORE, J. O., GANDHI, V., BLANEY, S., GOLD, S., ERNST, T., HENSLEEDOWNEY, J., CHANG, A., KISOR, D., PLUNKETT, W. & MITCHELL, B. 1996. 2-amino-9-B-D-arabinosyl-6-methoxy-9H-guanine (GW 506U; compound 506U) is highly active in patients with T-cell malignancies: Results of a phase I trial in pediatric and adult patients with refractory hematological malignancies. Blood, 88, 2666-2666.
    • LAMBE, C. U., AVERETT, D. R., PAFF, M. T., REARDON, J. E., WILSON, J. G. & KRENITSKY, T. A. 1995. 2-Amino-6-methoxypurine arabinoside: an agent for Tcell malignancies. Cancer Res, 55, 3352-6.
    • LANE, P. J. & LUBATKIN, M. 1998. Relative Absorptive Capacity and Interorganizational Learning. Strategic Management Journal, 19, 461-477.
    • LASKE, D. W., YOULE, R. J. & OLDFIELD, E. H. 1997. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nature Medicine, 3, 1362-1368.
    • LAURELL, C. B. 1951. WHAT IS THE FUNCTION OF TRANSFERRIN IN PLASMA. Blood, 6, 183-187.
    • LAW, J. 1987. Technology and heterogeneous engineering: the case of portuguese expansion. In: BIJKER, W. E., HUGHES, T. P. & PINCH, T. J. (eds.) The Social Construction of Technological Systems: New Directions in the Sociology and History of Technology. USA: MIT Press.
    • LEIPONEN, A. & HELFAT, C. E. 2011. Location, Decentralization, and Knowledge Sources for Innovation. Organization Science, 22, 641-658.
    • LEOPOLD, L. H., BERGER, M. S., CHENG, S. C., CORTES-FRANCO, J. E., GILES, F. J. & ESTEY, E. H. 2003. Comparative efficacy and safety of gemtuzumab ozogamicin monotherapy and high-dose cytarabine combination therapy in patients with acute myeloid leukemia in first relapse. Clin Adv Hematol Oncol, 1, 220-5.
    • LEWENSTEIN, B. V. 1995. Science in the Media. In: JASANOFF, S., MARKLE, G. E., PETERSEN, J. C. & PINCH, T. (eds.) Handbook of Science and Technology Studies. SAGE Publications.
    • LEWI, P. J. & SMITH, A. 2007. Successful pharmaceutical discovery: Paul Janssen's concept of drug research. R&D Management, 37, 355-362.
    • LIEBESKIND, J. P., OLIVER, A. L., ZUCKER, L. & BREWER, M. 1996. Social networks, Learning, and Flexibility: Sourcing Scientific Knowledge in New Biotechnology Firms. Organization Science, 7, 428-443.
    • LIGHT, D. W. & WARBURTON, R. 2011. Demythologizing the high costs of pharmaceutical research. BioSocieties, 6, 34-50.
    • LIM, S. H., HALE, G., MARCUS, R. E., WALDMANN, H. & BAGLIN, T. P. 1993. CAMPATH-1 MONOCLONAL-ANTIBODY THERAPY IN SEVERE REFRACTORY AUTOIMMUNE THROMBOCYTOPENIC PURPURA. British Journal of Haematology, 84, 542-544.
    • LIN, A. J., COSBY, L. A., SHANSKY, C. W. & SARTORELLI, A. C. 1972. Potential bioreductive alkylating agents. 1. Benzoquinone deriviatives. . Journal of Medicinal Chemistry, 15, 1247-1252.
    • LINENBERGER, M. L. 2004. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia, 19, 176-182.
    • LIPSKY, M. S. & SHARP, L. K. 2001. From Idea to Market: The Drug Approval Process. Journal of the American Board of Family Practice, 14, 362-367.
    • LIU, J. K. H. 2014. The history of monoclonal antibody development - Progress, remaining challenges and future innovations. Annals of Medicine and Surgery, 3, 113-116.
    • LONDON STOCK EXCHANGE AGGREGATED REGULATORY NEWS SERVICE. 1996. Celltech Group PLC Clinical Studies Results. December 9, 1996.
    • LONDON STOCK EXCHANGE AGGREGATED REGULATORY NEWS SERVICE. 2001. KS Biomedix Holdings Final Results. September 24, 2001.
    • LONDON STOCK EXCHANGE AGGREGATED REGULATORY NEWS SERVICE. 2006a. AstraZeneca PLC Interim Results - Part 1 of 2 -4-. July 27, 2006.
    • LONDON STOCK EXCHANGE AGGREGATED REGULATORY NEWS SERVICE 2006b. Protherics PLC Interim Results - Part 1-2-. London Stock Exchange Aggregated Regulatory News Service
    • LOUGHNOT, D. 2005. Potential interactions of the Orphan Drug Act and pharmacogenomics: a flood of orphan drugs and abuses? Am J Law Med, 31, 365-80.
    • LOUVET, C., ANDRE, T., GAMELIN, E., GARCIA, M. L., SAAVEDRA, A., LENAERS, G., DE GRAMONT, A., MERY-MIGNARD, D. & KALLA, S. 2004. A phase I-II, dose-escalating trial of ZD9331 in combination with irinotecan (CPT11) in previously pretreated metastatic colorectal cancer patients. Bulletin du cancer, 91, 279-84.
    • LOWENBERG, B., MUUS, P., OSSENKOPPELE, G., ROUSSELOT, P., CAHN, J. Y., IFRAH, N., MARTINELLI, G., AMADORI, S., BERMAN, E., SONNEVELD, P., JONGEN-LAVRENCIC, M., RIGAUDEAU, S., STOCKMAN, P., GOUDIE, A., FADERL, S., JABBOUR, E. & KANTARJIAN, H. 2011. Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. Blood, 118, 6030-6.
    • LUNDIN, J., OSTERBORG, A., BRITTINGER, G., CROWTHER, D., DOMBRET, H., ENGERT, A., EPENETOS, A., GISSELBRECHT, C., HUHN, D., JAEGER, U., THOMAS, J., MARCUS, R., NISSEN, N., POYNTON, C., RANKIN, E., STAHEL, R., UPPENKAMP, M., WILLEMZE, R., MELLSTEDT, H. & EUROPEAN STUDY GRP, C. H. T. L. G. 1998. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: A phase II multicenter study. Journal of Clinical Oncology, 16, 3257-3263.
    • LUNT, E., STEVENS, M. F. G., STONE, R., WOOLDRIDGE, K. R. H. & NEWLANDS, E. S. 1993. Antitumor. Google Patents.
    • MACHER, J. T. & BOERNER, C. 2012. Technological development at the boundaries of the firm: a knowledge-based examination in drug development. Strategic Management Journal, 33, 1016-1036.
    • MACHER, J. T. & BOERNER, C. S. 2006. Experience and Scale and Scope Economies: Trade-Offs and Performance in Development. Strategic Management Journal, 27, 845-865.
    • MAEVIS, V., MEY, U., SCHMIDT-WOLF, G. & SCHMIDT-WOLF, I. G. H. 2014. Hairy cell leukemia: short review, today/'s recommendations and outlook. Blood Cancer Journal, 4, e184.
    • MAGAZZINI, L., PAMMOLLI, F. & RICCABONI, M. 2010. Market Structure, Sunk Costs and Scope Economies in Pharmaceutical R&D. Available: http://www.webmeets.com/files/papers/EARIE/2010/333/MPR_EARIE.pdf.
    • MAIESE, W. M., LECHEVALIER, M. P., LECHEVALIER, H. A., KORSHALLA, J., KUCK, N., FANTINI, A., WILDEY, M. J., THOMAS, J. & GREENSTEIN, M. 1989. CALICHEAMICINS, A NOVEL FAMILY OF ANTITUMOR ANTIBIOTICS - TAXONOMY, FERMENTATION AND BIOLOGICAL PROPERTIES. Journal of Antibiotics, 42, 558-563.
    • MALERBA, F. & ORSENIGO, L. 2002. Innovation and market structure in the dynamics of the pharmaceutical industry and biotechnology: towards a history‐friendly model. Industrial and Corporate Change, 11, 667-703.
    • MANCHESTER EVENING NEWS. 2004. Snake venom firm is biting back into black. Manchester Evening News, December 8, 2004.
    • MARKET WIRE. 2005. Xenova Group Plc announces Offer by Celtic Pharma Part I. June 23, 2005.
    • MARKET WIRE 2008. Novacea Update on Asentar. Market Wire. South San Francisco.
    • MARKHAM, S. K. 2000. Corporate Championing and Antagonism as Forms of Political Behavior: An R&D Perspective. Organization Science, 11, 429-447.
    • MARKHAM, S. K., GREEN, S. G. & BASU, R. 1991. Champions and antagonists: Relationships with r&d project characteristics and management. Journal of Engineering and Technology Management, 8, 217-242.
    • MARKHAM, S. K. & GRIFFIN, A. 1998. The Breakfast of Champions: Associations Between Champions and Product Development Environments, Practices and Performance. Journal of Product Innovation Management, 15, 436-454.
    • MARKS, L. 2013a. The life story of a biotechnology drug: Alemtuzumab [Online]. www.whatisbiotechnology.org.
    • MARKS, L. 2013b. The Story of Cesar Milstein and Monoclonal Antibodies [Online]. www.whatisbiotechnology.org.
    • MARKS, L. 2015. The Lock and Key of Medicine: Monoclonal antibodies and the transformation of healthcare, London, Yale University Press.
    • MARTIN, P., BROWN, N., KRAFT, A. 2008 From Bedside to Bench? Communities of Promise, Translational Research and the Making of Blood Stem Cells. Science as Culture, 17:1, 29-41.
    • MARTIN, P., HOPKINS, M., NIGHTINGALE, P. & KRAFT, A. 2009. On a critical path: genomics, the crisis of pharmaceutical productivity and the search for sustainability. In: ATKINSON, P., GLASNER, P. & LOCK, M. (eds.) Handbook of Genetics and Society: Mapping the New Genomic Era. Oxon, UK: Routledge International Handbooks.
    • MARTIN, P. A. 1999. Genes as drugs: the social shaping of gene therapy and the reconstruction of genetic disease. Sociology of Health and Illness, 21, 517-538.
    • MATTESON, E. L., YOCUM, D. E., STCLAIR, E. W., ACHKAR, A. A., THAKOR, M. S., JACOBS, M. R., HAYS, A. E., HEITMAN, C. K. & JOHNSTON, J. M. 1995. TREATMENT OF ACTIVE REFRACTORY RHEUMATOID-ARTHRITIS WITH HUMANIZED MONOCLONAL-ANTIBODY CAMPATH-1H ADMINISTERED BY DAILY SUBCUTANEOUS INJECTION. Arthritis and Rheumatism, 38, 1187-1193.
    • MCCAVANA, S. 2002. Ulster Prof in cancer trials breakthrough; 'I hope ... the second phase of trials will take place in Belvoir Hospital'. Sunday Life, April 25, 2003.
    • MCINTYRE, J. 2001. 'Cancer-busting drug' developed;. Irish News, September 27, 2001.
    • MCKEOWN, S. R., COWEN, R. L. & WILLIAMS, A. J. 2007. Bioreductive Drugs: from Concept to Clinic. Clinical Oncology, 19, 427-442.
    • MCKEOWN, S. R., HEJMADI, M. V., MCINTYRE, I. A., MCALEER, J. J. & PATTERSON, L. H. 1995. AQ4N: an alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in vivo. Br J Cancer, 72, 76-81.
    • MEDICAL DEVICE DAILY. 1999. AstraZeneca set to tackle culture difficulties of merger. April 15, 1999.
    • MEDICENNA THERAPEUTICS INC. 2014. Management and Advisors - Fahar Merchant [Online]. Available: http://www.medicenna.com/our-team.html [Accessed September 23, 2014.
    • MEEKINGS, K. N., WILLIAMS, C. S. M. & ARROWSMITH, J. E. 2012. Orphan drug development: an economically viable strategy for biopharma R&D. Drug Discovery Today, 17, 660-664.
    • MIDDLETON, M. R., KNOX, R., CATTELL, E., OPPERMANN, U., MIDGLEY, R., ALI, R., AUTON, T., AGARWAL, R., ANDERSON, D., SARKER, D., JUDSON, I., OSAWA, T., SPANSWICK, V. J., DAVIES, S., HARTLEY, J. A. & KERR, D. J. 2010. Quinone Oxidoreductase-2-Mediated Prodrug Cancer Therapy. Science Translational Medicine, 2, 40ra50.
    • MILLENNIUM PHARMACEUTICALS, I. A. L., INC., 1999. Millennium and Leukosite Agree To Merge To Accelerate Millennium's Move Toward Commercialization;- Provides Millennium with Enhanced Clinical Development Capabilities and Product Pipeline -. PR Newswire. Cambridge, Mass, USA.
    • MILLER, D. R. 2006. A tribute to Sidney Farber - the father of modern chemotherapy. British Journal of Haematology, 134, 20-26.
    • MINNECI, B. 1999. Kids reach out to 2 classmates; Saturday's 'Kans for Kids' to aid patient, fire victim. The Patriot Ledger, October 14, 1999
    • MIYAWAKI, S., ANDO, K., YOKOZAWA, T., YAMAUCHI, T., WATANABE, T., FUJISAWA, S., UIKE, N., SAKURA, T., YAGAWA, K. & HOTTA, T. 2010. A PHASE I STUDY OF AZD1152, AN AURORA B KINASE INHIBITOR, IN JAPANESE PATIENTS WITH ADVANCED ACUTE MYELOID LEUKEMIA. Annals of Oncology, 21, 176-176.
    • MONTANER, J. S. G., O'SHAUGHNESSY, M. V. & SCHECHTER, M. T. 2001. Industrysponsored clinical research: a double-edged sword. The Lancet, 358, 1893-1895.
    • MOORE, C. 2005. GSK expects cancer drug sales to double by 2009. The Guardian, December 1, 2005, p.pg. 27.
    • MOORE, M. J., FELD, R., HEDLEY, D., OZA, A. & SIU, L. L. 1998. A phase II study of Temozolomide in advanced untreated pancreatic cancer. Investigational New Drugs, 16, 77-79.
    • MOORE, S. W. 2003. An overview of drug development in the United States and current challenges. Southern Medical Journal, 96, 1244-1255.
    • MOORS, E. H. M., BOON, W. P. C., NAHUIS, R. & VANDEBERG, R. L. J. 2008. UserProducer Interactions in Emerging Pharmaceutical and Food Innovations. International Journal of Innovation Management, 12, 459-487.
    • MOORS, E. H. M., COHEN, A. F. & SCHELLEKENS, H. 2014. Towards a sustainable system of drug development. Drug Discovery Today, 19, 1711-1720.
    • MOORS, E. H. M., FABER, J., HEKKERT, M. P. & MEEUS, M. 2002. Innovation system barriers in orphan drug development within the Netherlands. 10th International Conference of the Greening of Industry Network. Goteborg, Sweden.
    • MORAN, P. 2005. Structural vs. Relational Embeddedness: Social Capital and Managerial Performance. Strategic Management Journal, 26, 1129-1151.
    • MORROW, K. J. 2012. The New Generation of Antibody Therapeutics: Current Status and Future Prospects - Overview. PR Newswire. New York, UK.
    • MORTLOCK, A. A., FOOTE, K. M., HERON, N. M., JUNG, F. H., PASQUET, G., LOHMANN, J. J., WARIN, N., RENAUD, F., DE SAVI, C., ROBERTS, N. J., JOHNSON, T., DOUSSON, C. B., HILL, G. B., PERKINS, D., HATTER, G., WILKINSON, R. W., WEDGE, S. R., HEATON, S. P., ODEDRA, R., KEEN, N. J., CRAFTER, C., BROWN, E., THOMPSON, K., BRIGHTWELL, S., KHATRI, L., BRADY, M. C., KEARNEY, S., MCKILLOP, D., RHEAD, S., PARRY, T. & GREEN, S. 2007. Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase. J Med Chem, 50, 2213-24.
    • MOWERY, D. & ROSENBERG, N. 1979. The Influence of Market Demand upon Innovation: a critical review of some recent empirical studies. Research Policy, 8, 102-153.
    • MOWERY, D. C., OXLEY, J. E. & SILVERMAN, B. S. 1996. Strategic alliances and interfirm knowledge transfer. Strategic Management Journal, 17, 77-91.
    • MUKHERJEE, S. 2011. The Emperor of All Maladies, HarperCollins Publishers.
    • MULLEN, A., BLUNCK, M., KALBFLEISCH, E., MOLLER, E. & ROHBECK, H. G. 1997. Assessment, from an industry user perspective of some major competitor information files on pharmaceutical development products. Journal of Information Science, 23, 9-23.
    • MUMFORD, M. D., SCOTT, G. M., GADDIS, B. & STRANGE, J. M. 2002. Leading creative people: Orchestrating expertise and relationships. The Leadership Quarterly, 13, 705-750.
    • NAHAPIET, J. & GHOSHAL, S. 1998. Social Capital, Intellectual Capital, and the Organizational Advantage. Academy of Management Review, 23, 242-266.
    • NAHUIS, R. & BOON, W. P. 2011. The impact of patient advocacy: the case of innovative breast cancer drug reimbursement. Sociol Health Illn, 33, 1-15.
    • NATIONAL CANCER INSTITUTE 2001. High Response Rate of Hairy Cell Leukemia Patients to Immunotoxin Treatment Raises Hopes. In: NEWS, N. (ed.). USA: National Cancer Institute.
    • NATIONAL CANCER INSTITUTE. 2013. FDA Approval for Sorafenib Tosylate [Online]. USA. Available: http://www.cancer.gov/cancertopics/druginfo/fda-sorafenibtosylate [Accessed September 30, 2014 2014].
    • NATIONAL CANCER INSTITUTE. 2014. Timeline [Online]. USA: National Cancer Institute. [Accessed October 15 2014].
    • NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) 2001a. Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer). NICE Technology Appraisals. London, UK.
    • NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) 2001b. A Review of the Evidence for the Clinical and Cost-effectiveness of Irinotecan, Oxaliplatin and Raltitrexed for the Treatment of Advanced Colorectal Cancer. United Kingdom.
    • NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) 2005. Overview - The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer (review of Technology Appraisal Guidance No. 33). United Kingdom.
    • NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) 2009. Sunitinib for the first-line treatment of advanced and/or metastatic renal cell caricnoma. Technology appraisals London, UK: NICE.
    • NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) 2010. Sorafenib for the treatment of advanced hepatocellular carcinoma Technology Appraisals. London, UK.
    • NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) 2011. Pazopanib for the first-line treatment of advanced renal cell carcinoma. Technology appraisals London, UK: NICE.
    • NATIONAL INSTITUTES OF HEALTH 2013. National Center for Advancing Translational Sciences, Office of Rare Diseases Research and National Human Genome Research Institute Information Sheet (NIH Publication No. 05-5212). In: CENTER, N. I. O. H. G. A. R. D. I. (ed.). USA.
    • NEAL, R. 2012. Clinical trials: design and practice. In: O'NEILL, M. & HOPKINS, M. M. (eds.) A Biotech Manager's Handbook. Oxford, UK: Biohealthcare Publishing (Oxford) Ltd.
    • NELSON, A. L., DHIMOLEA, E. & REICHERT, J. M. 2010. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov, 9, 767-774.
    • NELSON, R. R. & WINTER, S. G. 1982. An evolutionary theory of economic change, Cambridge, Mass., Belknap P.
    • NERKAR, A. & ROBERTS, P. W. 2004. Technological and product-market experience and the success of new product introductions in the pharmaceutical industry. Strategic Management Journal, 25, 779-799.
    • NEWELL, D. R., SEARLE, K. M., WESTWOOD, N. B., BURTLES, S. S. & CANCER RESEARCH, U. K. P. I. I. I. C. T. C. 2003. Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK. British Journal of Cancer, 89, 437-454.
    • NEWLANDS, E. S., BLACKLEDGE, G., SLACK, J. A., GODDARD, C., BRINDLEY, C. J., HOLDEN, L. & STEVENS, M. F. 1985. Phase I clinical trial of mitozolomide. Cancer Treat Rep, 69, 801-5.
    • NEWLANDS, E. S., BLACKLEDGE, G. R. P., SLACK, J. A., RUSTIN, G. J. S., SMITH, D. B., STUART, N. S. A., QUARTERMAN, C. P., HOFFMAN, R., STEVENS, M. F. G., BRAMPTON, M. H. & GIBSON, A. C. 1992. ANTITUMOR IMIDAZOTETRAZINES .26. PHASE-I TRIAL OF TEMOZOLOMIDE (CCRG81045, M-AND-B 39831, NSC-362856). British Journal of Cancer, 65, 287-291.
    • NEWLANDS, E. S., OREILLY, S. M., GLASER, M. G., BOWER, M., EVANS, H., BROCK, C., BRAMPTON, M. H., COLQUHOUN, I., LEWIS, P., RICEEDWARDS, J. M., ILLINGWORTH, R. D. & RICHARDS, P. G. 1996. The Charing Cross Hospital experience with temozolomide in patients with gliomas. European Journal of Cancer, 32A, 2236-2241.
    • NICHOLSON, H. S., KRAILO, M., AMES, M. M., SEIBEL, N. L., REID, J. M., LIU-MARES, W., VEZINA, L. G., ETTINGER, A. G. & REAMAN, G. H. 1998. Phase I study of temozolomide in children and adolescents with recurrent solid tumors: A report from the children's cancer group. Journal of Clinical Oncology, 16, 3037-3043.
    • NICHOLSON, S., DANZON, P. M. & MCCULLOUGH, J. 2005. Biotech‐Pharmaceutical Alliances as a Signal of Asset and Firm Quality. The Journal of Business, 78, 1433-1464.
    • NICOL, D., HII, S. I., WALSH, M., TEH, B., THOMPSON, L., KENNETT, C. & GOTLEY, D. 1997. Vascular endothelial growth factor expression is increased in renal cell carcinoma. J Urol, 157, 1482-6.
    • NICULESCU-DUVAZ, I. 2000. ZD-9331 AstraZeneca. Curr Opin Investig Drugs, 1, 141- 9.
    • NIELSEN, B. B. & NIELSEN, S. 2009. Learning and Innovation in International Strategic Alliances: An Empirical Test of the Role of Trust and Tacitness. Journal of Management Studies, 46, 1031-1056.
    • NIGHTINGALE, P. 2000. Economies of scale in experimentation: knowledge and technology in pharmaceutical R&D. Industrial and Corporate Change, 9, 315-359.
    • NIGHTINGALE, P., BADEN-FULLER, C. & HOPKINS, M. M. 2011. Projects, Project Capabilities and Project Organizations. Project-Based Organizing and Strategic Management.
    • NIGHTINGALE, P. & MARTIN, P. 2004. The myth of the biotech revolution. Trends Biotechnol, 22, 564-569.
    • NIOSI, J. 2003. Alliances are not enough explaining rapid growth in biotechnology firms. Research Policy, 32, 737-750.
    • NIXON, R. 1971. 26 - Annual Message to the Congres on the State of the Union. XXXVII President of the United States: 1969-1974.
    • NOVACEA 2003. Novacea Licenses Novel Anti-Cancer Product Candidate From KuDOS Pharmaceuticals. Press Release. USA.
    • NOVACEA 2005a. Novacea Announces Three Presentations on Anti-Cancer Agent, Banoxantrone (AQ4N), at AACR Meeting Press Release. USA.
    • NOVACEA 2005b. Novacea Begins Phase 1/2 Trial of Anti-Cancer Agent Banoxantrone (AQ4N) in Patients With Lymphoma; - Multi-Center Study Will Determine Dosing, Tolerability, Pharmacoki-netics and Initial Response Rates Press Release. USA.
    • NOVACEA 2006a. Annual Report.
    • NOVACEA 2006b. Novacea Initiates Phase 1/2 Trial of AQ4N in Glioblastoma Multiforme. Press Release. USA.
    • NOVACEA 2006c. Novacea to Focus Development Attention and Resources on Oncology Product Candidates, Asentar and AQ4N; Novacea and Pierre Fabre Agree to Terminate U.S. and Canadian Li-censing Agreement for Vinorelbine Oral. Press Release. USA.
    • NOVACEA 2007a. Novacea Acquires Worldwide Development and Commercialization Rights for Its Oncology Candidate AQ4N. Press Release. USA.
    • NOVACEA 2007b. Novacea Initiates Phase 2 Trial of AQ4N in Acute Lymphoblastic Leukemia. Press Release. USA.
    • NOVACEA 2009. Novacea Stockholders Approve Merger With Transcept. Press Release. USA.
    • NOWELL, P. & HUNGERFORD, D. 1960. A minute chromosome in human chronic granulocytic leukemia. Science, 132, 1497.
    • NOWELL, P. C. & HUNGERFORD, D. A. 1961. Chromosome studies in human leukemia. II. Chronic granulocytic leukemia. J Natl Cancer Inst, 27, 1013-35.
    • NUFFIELD COUNCIL ON BIOETHICS 2012. Emerging biotechnologies: technology, choice and the public good. London, UK: Nuffield Council on Bioethics.
    • O'SHEA, S. 1992. CANCER DRUG COULD BRING £20m BONUS FROM CHARITY. Daily Mail, June 29, 1992, p.Pg. 5.
    • OLIVER, A. L. 2004. Biotechnology entrepreneurial scientists and their collaborations. Research Policy, 33, 583-597.
    • OLSON, T. A., MOHANRAJ, D., CARSON, L. F. & RAMAKRISHNAN, S. 1994. Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Res, 54, 276-80.
    • OREILLY, S. M., NEWLANDS, E. S., GLASER, M. G., BRAMPTON, M., RICEEDWARDS, J. M., ILLINGWORTH, R. D., RICHARDS, P. G., KENNARD, C., COLQUHOUN, I. R., LEWIS, P. & STEVENS, M. F. G. 1993. TEMOZOLOMIDE - A NEW ORAL CYTOTOXIC CHEMOTHERAPEUTIC AGENT WITH PROMISING ACTIVITY AGAINST PRIMARY BRAIN-TUMORS. European Journal of Cancer, 29A, 940-942.
    • ORSENIGO, L., PAMMOLLI, F. & RICCABONI, M. 2001. Technological change and network dynamics: Lessons from the pharmaceutical industry. Research Policy, 30, 485-508.
    • OSTERBORG, A., DYER, M. J. S., BUNJES, D., PANGALIS, G. A., BASTION, Y., CATOVSKY, D., MELLSTEDT, H., RANKIN, E., TSEKOURAS, C., PANGALIS, G. A., CAVALLI, F., SESSA, C., HUHN, D., MARCUS, R., MAUGHAN, T., POYNTON, C., NISSEN, N., CARNEY, D., BRITTINGER, G., UPPENKAMP, M., ELONEN, E., TEERENHOVI, L., ENGERT, WILLEMZE, R., KLUINNELEMANS, J., THOMAS, J., EPENETOS, A. A., NETHERSELL, A., DYER, M., CATOVSKY, D., DICATO, M., BASTION, Y., COIFFIER, B., RANADA, J. M. F., CROWTHER, D., WOLL, P., RAEMAKAERS, J., DEPAUW, B., DEGOS, L., GISSELLBRECHT, REIFFERS, J., MELLSTEDT, H., FASSAS, A., ANAGNOSTOPOULOS, A., BUNJES, D., JAEGER, U. & STAHEL, R. A. 1997a. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. Journal of Clinical Oncology, 15, 1567-1574.
    • OSTERBORG, A., FASSAS, A. S., ANAGNOSTOPOULOS, A., DYER, M. J. S., CATOVSKY, D. & MELLSTEDT, H. 1996. Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. British Journal of Haematology, 93, 151-153.
    • OSTERBORG, A., WERNER, A., HALAPI, E., LUNDIN, J., HARMENBERG, U., WIGZELL, H. & MELLSTEDT, H. 1997b. Clonal CD8(+) and CD52(-) T cells are induced in responding B cell lymphoma patients treated with Campath-1H (antiCD52). European Journal of Haematology, 58, 5-13.
    • OWEN, G. & HOPKINS, M. M. 2016. Science, The State and The City: Britain's Struggle for Success in Biotechnology, Oxford, UK, Oxford University Press.
    • PAGNAMENTA, R. 2007. GSK may offer 'money back' guarantees. The Times, June 5, 2007, p.Pg. 53.
    • PAMMOLLI, F., MAGAZZINI, L. & RICCABONI, M. 2011. The productivity crisis in pharmaceutical R&D. Nat Rev Drug Discov, 10, 428-38.
    • PAPADOPOULOS, K. P., GOEL, S., BEERAM, M., WONG, A., DESAI, K., HAIGENTZ, M., MILIAN, M. L., MANI, S., TOLCHER, A., LALANI, A. S. & SARANTOPOULOS, J. 2008. A phase 1 open-label, accelerated dose-escalation study of the hypoxiaactivated prodrug AQ4N in patients with advanced malignancies. Clinical Cancer Research, 14, 7110-5.
    • PAPP, L. 1996. New breast cancer drug may beat side-effects Early tests excite research teams. The Toronto Star, April 24, 1996.
    • PARUCHURI, S. 2010. Intraorganizational Networks, Interorganizational Networks, and the Impact of Central Inventors: A Longitudinal Study of Pharmaceutical Firms. Organization Science, 21, 63-80.
    • PARUCHURI, S., NERKAR, A. & HAMBRICK, D. C. 2006. Acquisition Integration and Productivity Losses in the Technical Core: Disruption of Inventors in Acquired Companies. Organization Science, 17, 545-562.
    • PASTAN, I. 2003. Immunotoxins containing Pseudomonas exotoxin A: a short history. Cancer Immunology, Immunotherapy, 52, 338-341.
    • PASTAN, I., CHAUDHARY, V., FITZGERALD, D. & BATRA, J. 2000. Recombinant immunotoxin composed of a single chain antibody reacting with the human transferrin receptor and diptheria toxin.
    • PATTERSON, L. H. 1993. Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent. Cancer Metastasis Rev, 12, 119-34.
    • PAVITT, K. 1984. Sectoral patterns of technical change: Towards and taxonomy and a theory. Research Policy, 13, 343-373.
    • PAVITT, K. 1999. Introduction. In: PAVITT, K. (ed.) Technology, Management and Systems of Innovation. Cheltenham, UK and Northampton, USA: Edward Elgar Publishing.
    • PEGG, S. J. & WARDLEWORTH, J. M. 1999a. Anti-tumour Quinazolinon Derivatives. GB19930004807 19930309
    • PEGG, S. J. & WARDLEWORTH, J. M. 1999b. Antitumor, antiinflammatory, and antiarthritic agents. Google Patents.
    • PENNA, C. C. R. & GEELS, F. W. 2012. Multi-dimensional struggles in the greening of industry: A dialectic issue lifecycle model and case study. Technological Forecasting and Social Change, 79, 999-1020.
    • PERSEUS LLC. Millennium/LeukoSite [Online]. USA. [Accessed September 26 2014].
    • PETRUZELKA, L. 2003. Phase II multicentre trial of ZD9331 monotherapy as first-line treatment for gastric cancer. Anti-Cancer Drugs, 14, S7-S12.
    • PHARMA MARKETLETTER 1992. Genentech's Expanding Product Portfolio. Pharma Marketletter.
    • PHARMA MARKETLETTER. 1993a. CELLTECH PRODUCT PIPELINE UPDATE. Pharma Marketletter, May 24, 1993.
    • PHARMA MARKETLETTER. 1993b. Celltech Unveils Strong R&D Pipeline. Pharma Marketletter, November 22, 1993.
    • PHARMA MARKETLETTER. 1993c. WELLCOME REFOCUSING R&D EFFORTS. Pharma Marketletter, May 10, 1993.
    • PHARMA MARKETLETTER. 1994. AHP To Cut Jobs At Cyanamid. December 5, 1994.
    • PHARMA MARKETLETTER. 1995a. Celltech Shows Substantial Pipeline Progress. Pharma Marketletter.
    • PHARMA MARKETLETTER. 1995b. Evolving Treatment for Colorectal Cancer. Pharma Marketletter, November 20, 1995.
    • PHARMA MARKETLETTER. 1997a. An "Annus Horribilis" for Celltech. Pharma Marketletter, December 11, 1997.
    • PHARMA MARKETLETTER. 1997b. Celltech Refocuses On Lower-Risk Projects. May 30, 1997.
    • PHARMA MARKETLETTER. 1997c. Genentech Progresses with Breast Cancer Antibody. Pharma Marketletter, December 29, 1997.
    • PHARMA MARKETLETTER. 1997d. Roche Enters New Product Phase With Bright Prospects. Pharma Marketletter February 17, 1997.
    • PHARMA MARKETLETTER. 1997e. Zeneca Allays Fears of Near-Term Product Gap. Pharma Marketletter, December 4, 1997.
    • PHARMA MARKETLETTER. 2000a. Novartis' CML drug Glivec dominates ASH conference. Pharma Marketletter, December 5, 2000.
    • PHARMA MARKETLETTER. 2000b. Wyeth-Ayerst wins orphan drug status for Mylotarg in Europe. Pharma Marketletter, November 12, 2000.
    • PHARMA MARKETLETTER. 2001. KS Biomedix hit by arthritis drug setback. December 7, 2001.
    • PHARMA MARKETLETTER. 2005a. Cambridge Antibody Technology Announces Preliminary Results for the Year Ended 30 September 2005. November 28, 2005 PHARMA MARKETLETTER. 2005b. CAT acquires two Genencor candidates. Pharma Marketletter November 3, 2005.
    • PHARMA MARKETLETTER. 2005c. FDA approved GSK's cancer drug Arranon. November 1, 2005.
    • PHILLIPS, H., ARMANI, M., STAVROU, D., FERRARA, N. & WESTPHAL, M. 1993. Intense focal expression of vascular endothelial growth-factor messenger-RNA in human intracranial neoplasms - association with regions of necrosis. Int J Oncol, 2, 913-9.
    • PINCH, T. & BIJKER, W. E. 1984. The Social Construction of Facts and Artefacts: or How the Sociology of Science and the Sociology of Technology might Benefit Each Other. Social Studies of Science, 14, 339-441.
    • PISANO, G. P. 2006. Science Business, Harvard Business School Press.
    • PLATE, K. H., BREIER, G., WEICH, H. A. & RISAU, W. 1992. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature, 359, 845-8.
    • PLUMMER, R., REES, C., HUGHES, A., BEALE, P., HIGHLEY, M., TRIGO, J., GOKUL, S., JUDSON, I., CALVERT, H., JACKMAN, A., MITCHELL, F., SMITH, R. & DOUGLASS, E. 2003. A phase I trial of ZD9331, a water-soluble, nonpolyglutamatable, thymidylate synthase inhibitor. Clinical Cancer Research, 9, 1313-1322.
    • PLUMMER, R., REES, C., JUDSON, I., CALVERT, H., HIGHLEY, M., TRIGO, J., JACKMAN, A., SMITH, R., HUTCHISON, M. & SMITH, M. 1999. Phase I trial of ZD9331 in adult patients with refractory solid malignancies administered by 30- min infusion on days 1 and 8 with the cycle repeated every 3 weeks. European Journal of Cancer, 35, S285-S285.
    • PM CYCLE 1996. Disappointing Biotech Innovation Shows Promise Against Cancer. PM Cycle.
    • POLANYI, M. 1958. Personal Knowledge: Towards a Post-Critical Philosophy, London, UK, Routledge & Kegan Paul.
    • PORTER, R. 1999. The Greatest Benefit to Mankind: A Medical History of Humanity from Antiquity to the Present, London, HarperCollins.
    • PORTER, R. 2002. Blood and Guts: A Short History of Medicine, London, UK, Penguin Books Ltd.
    • POWELL, W. W. 1996a. Inter-organizational collaboration in the biotechnology industry. Journal of Institutional and Theoretical Economics 151, 197-215.
    • POWELL, W. W. 1996b. Interorganizational Collaboration and the Locus of Innovation: Networks of Learning in Biotechnology. Administrative Science Quarterly, 41, 116-145.
    • POWERS, J. B. & MCDOUGALL, P. P. 2005. University start-up formation and technology licensing with firms that go public: a resource-based view of academic entrepreneurship. Journal of Business Venturing, 20, 291-311.
    • PR NEWSWIRE. 1986. PR Newswire.
    • PR NEWSWIRE. 1991. SCHERING-PLOUGH BRIEFS ANALYSTS ON RESEARCH PROGRESS, NEW PRODUCTS.
    • PR NEWSWIRE. 1994. BURROUGHS WELLCOME DRUG FOR NON-SMALL CELL LUNG CANCER APPROVED FOR U.S. MARKET. Press Release, December 27, 1994.
    • PR NEWSWIRE. 1996. SmithKline Beecham's Hycamtin Licensed For Marketing In European Union (EU) For Treatment Of Relapsed Ovarian Cancer. Press Release, November 14, 1996.
    • PR NEWSWIRE. 1997. Revlon Hails the Development of a New Gene Based Breast Cancer Drug. Business Wire, December 19, 1997.
    • PR NEWSWIRE 1999. Another Volatile - Though Generally Positive - Quarter for Biotechnol-ogy; The Gaps Widen Between the Tiers as Products and Profits Increasingly Separate The 'Haves' From the 'Have-Nots'. PR Newswire. San Francisco, USA.
    • PRABHU, J. C., CHANDY, R. K. & ELLIS, M. E. 2005. The Impact of Acquisitions on Innovation: Poison Pill, Placebo, or Tonic? Journal of Marketing, 69, 114-130.
    • PRATT, W. B. & RUDDON, R. W. 1979. The Anticancer Drugs, New York, Oxford University Press.
    • PRESSMAN, D. & KORNGOLD, L. 1953. The in vivo localization of anti-Wagnerosteogenic-sarcoma antibodies. Cancer, 6, 619-23.
    • PROTHERICS, P. 2003a. Annual Report. London, UK.
    • PROTHERICS, P. 2003b. Protherics plc Cash Placing and Open Offer by WestLB Panmure Limited of up to 18,804,468 new ordinary shares of 2 pence each at 16 pence per share.
    • PROTHERICS, P. 2003c. Recommended Offer By WestLB Panmure Limited on behalf of Protherics plc to acquire the whole of the issued and to be issued share capital of Enact Pharma plc.
    • PROTHERICS, P. 2005a. Annual Report. London, UK.
    • PROTHERICS, P. 2005b. Protherics PLC Interim Results -2-. Decem ber 8, 2005.
    • PROTHERICS, P. 2006. Annual Report. London, UK.
    • PROTHERICS, P. 2007a. Annual Report. London, UK.
    • PROTHERICS, P. 2007b. Protherics PLC Interim Management Statement. July 26, 2007.
    • PROTHERICS, P. 2008a. Annual Report. London, UK.
    • PROTHERICS, P. 2008b. Start of Prolarix (TM) phase 2 study in liver cancer August 27, 2008.
    • PUZZANGHERA, J. 1997. Drug Lottery: A Life-And-Death Gamble Deciding Who Gets Treated Poses Ethical Question. San Jose Mercury News (California) January 18, 1997.
    • QSV BIOLOGICS. 2004. QSV Biologics, Ltd. and the Xenova Group plc Sign Phase III Therapeutic Manufacturing Agreement. Press Release, September 8, 2004.
    • QUIRKE, V. & GAUDILLIÈRE, J.-P. 2008. The Era of Biomedicine: Science, Medicine, and Public Health in Britain and France after the Second World War. Medical History, 52, 441-452.
    • RADER, J. S., CLARKE-PEARSON, D., MOORE, M., CARSON, L., HOLLOWAY, R., KAO, M. S., WIZNITZER, I. & DOUGLASS, E. C. 2003. A phase 11 study to determine the efficacy and tolerability of intravenous ZD9331 in heavily pretreated patients with ovarian cancer. Gynecologic Oncology, 91, 318-325.
    • RAGIN, C. C. 1987. The comparative method : moving beyond qualitative and quantative strategies, Berkeley, Calif. ; London, University of California Press.
    • RAGIN, C. C. 1989. Comparative Method, The: Moving Beyond Qualitative and Quantitative Strategies, University of California Press.
    • RAGIN, C. C. 2000. Fuzzy-set social science, Chicago, Ill., University of Chicago Press.
    • RAGIN, C. C. 2008. Redesigning social inquiry : fuzzy sets and beyond, Chicago, Ill. Bristol, University of Chicago Press.
    • RANDALL, E. D. & FIX, J. L. 1994. American Home bids $ 8.5B for Cyanamid / Deal follows '90s formula: Synergy, size. USA Today, August 3, 1994.
    • RATAIN, M. J. & PLUNKETT, W. K. 2003. Pharmacology. In: KUFE, D. W., POLLOCK, R. E., WEICHSELBAUM, R. R., BAST, R. C., GANSLER, T. S., HOLLAND, J. F. & FREI, E. (eds.) Holland-Frei Cancer Medicine. 6th Edition ed. http://www.ncbi.nlm.nih.gov/books/NBK12354/: BC Decker.
    • REAGANS, R. & ZUCKERMAN, E. W. 2001. Networks, Diversity, and Productivity: The Social Capital of Corporate R&D Teams. Organization Science, 12, 502-517.
    • REECE, D. 2005. Make the sick pay, says Garnier GSK chief says governments must compel patients to fund own healthcare. The Daily Telegraph, December 1, 2005.
    • REES, C., BEALE, P., TRIGO, J. M., MITCHELL, F., JACKMAN, A., SMITH, R., DOUGLASS, E. & JUDSON, I. 2003. Phase I trial of ZD9331, a nonpolyglutamatable thymidylate synthase inhibitor, given as a 5-day continuous infusion to patients with refractory solid malignancies. Clinical Cancer Research, 9, 2049-2055.
    • REICHERT, J. M., ROCHON, S. L. & ZHANG, B. D. 2008. A decade of the Fast Track programme. Nat Rev Drug Discov, 7, 885-6.
    • REIST, E. J. & GOODMAN, L. 1964. SYNTHESIS OF 9-BETA-DARABINOFURANOSYLGUANINE. Biochemistry, 3, 15-8.
    • RESEARCH AND MARKETS 2005. Aurora Kinase inhibitors: The dawn of a new approach to cancer. USA: Research and Markets.
    • RESEARCH AND MARKETS. 2006. Monoclonal Antibodies, Generating $7.3 Billion in Sales in 2005, Have Been the Most Successful Class of Biological Anticancer Agents October 7, 2006.
    • REUTER. 1988. Scientists use magic bullets to treat cancer. The Toronto Star, December 16, 1988.
    • RHO VENTURES. LeukoSite [Online]. USA. [Accessed September 26 2014 ].
    • RIHOUX, B. & RAGIN, C. C. 2009. Configurational comparative methods : qualitative comparative analysis (QCA) and related techniques, London, SAGE.
    • ROBERTS, J. J., FRIEDLOS, F. & KNOX, R. J. 1986. CB 1954 (2,4-dinitro-5-aziridinyl benzamide) becomes a DNA interstrand crosslinking agent in Walker tumour cells. Biochem Biophys Res Commun, 140, 1073-8.
    • ROGERS, M. 1985. Interferon: A Cautionary Tale. Newsweek.
    • ROTHAERMEL, F. T. & HESS, A. M. 2007. Building Dynamic Capabilities: Innovation Driven by Individual-, Firm-, and Network-Level Effects. Organization Science, 18, 898-921.
    • ROTHWELL, R. 1992. Successful industrial innovation: critical factors for the 1990s. R&D Management, 22, 221-240.
    • ROTHWELL, R., FREEMAN, C. & HORLSEY, A. 1974. SAPPHO updated. Project SAPPHO phase II. Research Policy, 3, 258-291.
    • ROWLEY, J. D. 1973. A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining. Nature, 243, 290-293.
    • SALMAN, N. & SAIVES, A.-L. 2005. Indirect networks: an intangible resource for biotechnology innovation. R&D Management, 35, 203-215.
    • SANDOVAL, R. 1995. Genentech Fires Its CEO. San Jose Mercury News July 11, 1995.
    • SANSOM, C. 2009. Temozolomide - birth of a blockbuster. Chemistry World London, UK.
    • SARANTOPOULOS, J., TOLCHER, A., WONG, A., GOEL, S., BEERAM, M., LAM, G., DESAI, K., WOODY, K., MANI, S. & PAPADOPOULOS, K. 2006. Banoxantrone (AQ4N) tissue CYP 450 targeted prodrug: The results of a phase I study using an accelerated dose escalation. Journal of Clinical Oncology, 24, 2011.
    • SAWYER, M. B., RATAIN, M. J., BERTUCCI, D., SMITH, R. P., SCHILSKY, R. L., VOGELZANG, N. J., SHULMAN, K., DOUGLASS, E. C. & FLEMING, G. F. 2003. Phase I study of an oral formulation of ZD9331 administered daily for 28 days. Journal of Clinical Oncology, 21, 1859-1865.
    • SCANNELL, J. W., BLANCKLEY, A., BOLDON, H. & WARRINGTON, B. 2012. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov, 11, 191-200.
    • SCHERING-PLOUGH CORPORATION AND CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED. 1992. SCHERING-PLOUGH SIGNS WORLDWIDE AGREEMENT TO DEVELOP AND MARKET CANCER DRUG. June 26, 1992.
    • SCHERING PLOUGH. 1998. Schering-Plough Presents TEMODAL(R) Brain Cancer Studies At European Association for Neuro-Oncology Meeting. September 15, 1998.
    • SCHMOOKLER, J. 1966. Invention and Economic Growth.
    • SCHNEIDER, C. Q. & WAGEMANN, C. 2012. Set-Theoretical Methods for the Social Sciences: A Guide to Qualitative Comparative Analysis, New York, Cambridge University Press.
    • SCHON, D. A. 1963. Champions for Radical New Inventions. Harvard Business Review, 41, 77-86.
    • SCHOT, J. & GEELS, F. W. 2008. Strategic niche management and sustainable innovation journeys: theory, findings, research agenda, and policy. Technology Analysis & Strategic Management, 20, 537-554.
    • SCHULZ, J. & DOUGLASS, E. 2000. ZD9331 as second-or third-line therapy in patients with advanced colorectal cancer: A phase II multicentre trial. Annals of Oncology, 11, 62-62.
    • SCHULZ, J., KELLER, A., CANFIELD, V., PARKER, G. & DOUGLASS, E. 2004. ZD9331 as second- or third-line therapy in patients with advanced colorectal cancer - A phase II multicenter trial. American Journal of Clinical Oncology-Cancer Clinical Trials, 27, 337-342.
    • SCHWARTZ, G. H., JONES, C. B., GARRISON, M., PATNAIK, A., TAKIMOTO, C., MCCREERY, H., SKINNER, M., TOLCHER, A. W. & ROWINSKY, E. K. 2004. A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies. Investigational New Drugs, 22, 437-448.
    • SCHWEIZER, L. 2005. Organizational Integration of Acquired Biotechnology Companies into Pharmaceutical Companies: The Need for a Hybrid Approach. The Academy of Management Journal, 48, 1051-1074.
    • SCOTT, J. 2000. Social Network Analysis: A Handbook, London, UK, SAGE Publications Ltd.
    • SCOTTING, P. 2010. Cancer: A Beginners Guide, Oxford, UK, One World.
    • SCRIABINE, A. 1999a. Discovery and development of major drugs currently in use. In: LANDAU, R., ACHILLADELIS, B. & SCRIABINE, A. (eds.) Pharmaceutical Innovation: Revolutionizing Human Health. Chemical Heritage Foundation.
    • SCRIABINE, A. 1999b. The role of biotechnology in drug development. In: LANDAU, R., ACHILLADELIS, B. & SCRIABINE, A. (eds.) Pharmaceutical Innovation: Revolutionizing Human Health. Chemical Heritage Foundation.
    • SHAN, W., GORDON, W. & KOGUT, B. 1994. Interfirm Cooperation and Startup Innovation in the Biotechnology Industry. Strategic Management Journal, 15, 387-394.
    • SHWEIKI, D., ITIN, A., SOFFER, D. & KESHET, E. 1992. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature, 359, 843-5.
    • SIEVERS, E. L., APPELBAUM, F. R., SPIELBERGER, R. T., FORMAN, S. J., FLOWERS, D., SMITH, F. O., SHANNON-DORCY, K., BERGER, M. S. & BERNSTEIN, I. D. 1999a. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: A phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood, 93, 3678-3684.
    • SIEVERS, E. L., ARCECI, R., FRANKLIN, J., LANGE, B., SHANNON, K., SMITH, F., BERGER, M. S., ETEN, C. & AUEN, M. 2000. Preliminary report of an ascending dose study of gemtuzumab ozogamicin (Mylotarg (TM), CMA-676) in pediatric patients with acute myeloid leukemia. Blood, 96, 217B-217B.
    • SIEVERS, E. L., LARSON, R. A., ESTEY, E., STADTMAUER, E., BERGER, M., ETEN, C., BERNSTEIN, I. & APPELBAUM, F. 1998. Interim analysis of the efficacy and safety of CMA-676 in patients with AML in first relapse. Blood, 92, 613A-613A.
    • SIEVERS, E. L., LARSON, R. A., ESTEY, E., STADTMAUER, E. A., ERBA, H. P., ROY, D. C. C., TARANTOLO, L., SPIELBERGER, R., BERGER, M. S., ETEN, C., MANLEY, L., STONE, A., BERNSTEIN, I. & APPELBAUM, F. R. 1999b. Efficacy and safety of CMA-676 in patients with AML in first relapse. Blood, 94, 696A696A.
    • SIMON, F. 2006. Market access for biopharmaceuticals: New challenges. Health Affairs, 25, 1363-1370.
    • SINGH, Y., PALOMBO, M. & SINKO, P. J. 2008. Recent Trends in Targeted Anticancer Prodrug and Conjugate Design. Current Medicinal Chemistry, 15, 1802-1825.
    • SINHA, G. 2013. Antisense battles small molecule for slice of rare lipid disorder market. Nat Biotech, 31, 179-180.
    • SLAMON, D. J., CLARK, G. M., WONG, S. G., LEVIN, W. J., ULLRICH, A. & MCGUIRE, W. L. 1987. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235, 177-82.
    • SLAMON, D. J., GODOLPHIN, W., JONES, L. A., HOLT, J. A., WONG, S. G., KEITH, D. E., LEVIN, W. J., STUART, S. G., UDOVE, J., ULLRICH, A. & ET AL. 1989. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science, 244, 707-12.
    • SMITH, A. & RAVEN, R. 2012. What is protective space? Reconsidering niches in transitions to sustainability. Research Policy, 41, 1025-1036.
    • SMITH, D. & GALLAGHER, N. 2003. A phase II/III study comparing intravenous ZD9331 with gemcitabine in patients with pancreatic cancer. European Journal of Cancer, 39, 1377-1383.
    • SMITH, D. B., NEWLANDS, E. S., BLACKLEDGE, G., STUART, N. S. A., SLACK, J. & STEVENS, M. F. G. 1990. PHASE-I TRIAL OF TEMOZOLAMIDE (CCRG-81045, M-AND-B-39831, NSC-362856). British Journal of Cancer, 62, 519-520.
    • SMITHSON, M. & VERKUILEN, J. 2006. Fuzzy Set Theory: Applications in the Social Sciences, SAGE Publications.
    • SORESCU, A. B., CHANDY, R. K. & PRABHU, J. C. 2003. Sources and Financial Consequences of Radical Innovation: Insights from Pharmaceuticals. Journal of Marketing, 67, 82-102.
    • SOSEI CO. LTD. 2005. SOT-107 Granted Orphan Drug Designation in Japan. Press Release, February 14, 2005.
    • SOWTER, H. M., CORPS, A. N., EVANS, A. L., CLARK, D. E., CHARNOCK-JONES, D. S. & SMITH, S. K. 1997. Expression and localization of the vascular endothelial growth factor family in ovarian epithelial tumors. Lab Invest, 77, 607-14.
    • STAROPOLI, C. 1998. Cooperation in R&D in the pharmaceutical industry - The network as an organizational innovation governing technological innovation. Technovation, 18, 13-23.
    • STEHELIN, D., VARMUS, H. E., BISHOP, J. M. & VOGT, P. K. 1976. DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature, 260, 170-3.
    • STERNBERG, C. N., SZCZYLIK, C., LEE, E., SLAMAN, P., V. , MARDIAK, J., DAVIS, I. D., PANDITE, L., CHEN, M. H., MCCANN, L. & HAWKINS, R. A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokinepretreated patients with advanced renal cell carcinoma (RCC). ASCO Annual Meeting, 2009 Orlando, FL.: American Society of Clinical Oncology.
    • STEVENS, M. F., HICKMAN, J. A., LANGDON, S. P., CHUBB, D., VICKERS, L., STONE, R., BAIG, G., GODDARD, C., GIBSON, N. W., SLACK, J. A. & ET AL. 1987. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res, 47, 5846-52.
    • STEVENS, M. F., HICKMAN, J. A., STONE, R., GIBSON, N. W., BAIG, G. U., LUNT, E. & NEWTON, C. G. 1984. Antitumor imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)- one , a novel broad-spectrum antitumor agent. J Med Chem, 27, 196-201.
    • STEVENS, M. F. G. 2008. Chapter 7 - Temozolomide: From cytotoxic to molecularlytargeted agent. In: NEIDLE, S. (ed.) Cancer Drug Design and Discovery. New York: Academic Press.
    • STEVENS, M. F. G., RATHBONE, D. L. & O'SHEA, D. M. 1997. Triazenyl-substituted phenyl pyrimidines and their use in therapy.
    • STEWARD, W. P., MIDDLETON, M., BENGHIAT, A., LOADMAN, P. M., HAYWARD, C., WALLER, S., FORD, S., HALBERT, G., PATTERSON, L. H. & TALBOT, D. 2007. The use of pharmacokinetic and pharmacodynamic end points to determine the dose of AQ4N, a novel hypoxic cell cytotoxin, given with fractionated radiotherapy in a phase I study. Annals of Oncology, 18, 1098-103.
    • STEWART, J. & NAEYMI-RAD, N. 2011. Ten Trends Transforming the Business of Oncology. Oncology Business Review, September 2011, 24-28.
    • STIRLING, A. 2009. Direction, Distribution and Diversity! Pluralising Progress in Innovation, Sustainability and Development. STEPS Working Paper, 32, Brighton: STEPS Centre.
    • STOBBE, M. 1997. Trial drug is studied at Mayo; Shows hope in fight against brain cancer. Forida Times-Union, December 2, 1997, p.pg. C-6.
    • STREBHARDT, K. & ULLRICH, A. 2008. Paul Ehrlich's magic bullet concept: 100 years of progress. Nat Rev Cancer, 8, 473-80.
    • STROH, M., DUDA, D. G., TAKIMOTO, C. H., YAMAZAKI, S. & VICINI, P. 2014. Translation of anticancer efficacy from nonclinical models to the clinic. CPT Pharmacometrics Syst Pharmacol, 3, e128.
    • STUART, T. E. & DING, W. W. 2006. When Do Scientists Become Entrepreneurs? The Social Structural Antecedents of Commercial Activity in the Academic Life Sciences. American Journal of Sociology, 112, 97-144.
    • STUART, T. E., OZDEMIR, S. Z. & DING, W. W. 2007. Vertical alliance networks: The case of university-biotechnology-pharmaceutical alliance chains. Research Policy, 36, 477-498.
    • SUDHAKAR, A. 2009. History of Cancer, Ancient and Modern Treatment Methods. Journal of cancer science & therapy, 1, 1-4.
    • SUGEN, I. 1996. Preliminary Prospectus. NASDAQ, USA: Securities and Exchange Commission.
    • SUGEN, I. 1997. Annual Report.
    • SUGEN, I. 1998. SUGEN and Zeneca Discover New Oncogene, Aurora2, Overexpressed in More Than 50% of Colorectal Cancers and Subsets of Other Tumor Types. Press Release. USA.
    • SUNG, J. J. & HOPKINS, M. M. 2006. Towards a method for evaluating technological expectations: Revealing uncertainty in gene silencing technology discourse. Technology Analysis & Strategic Management, 18, 345-359.
    • SUZUKI, K., HAYASHI, N., MIYAMOTO, Y., YAMAMOTO, M., OHKAWA, K., ITO, Y., SASAKI, Y., YAMAGUCHI, Y., NAKASE, H., NODA, K., ENOMOTO, N., ARAI, K., YAMADA, Y., YOSHIHARA, H., TUJIMURA, T., KAWANO, K., YOSHIKAWA, K. & KAMADA, T. 1996. Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma. Cancer Res, 56, 3004-9.
    • TANSEY, E. M. & CATTERALL, P. P. 1997. Technology Transfer in Britain: The Case of Monoclonal Antibodies. The transcipt of a Witness Seminar held at the Wellcome Institute for the History of Medicine, London, on 24 September 1993. Wellcome Witnesses to Twentieth Century Medicine. London: Wellcome.
    • TEDDER, T. F., TUSCANO, J., SATO, S. & KEHRL, J. H. 1997. CD22, a B lymphocytespecific adhesion molecule that regulates antigen receptor signaling. Annu Rev Immunol, 15, 481-504.
    • TEECE, D. J. 1986. Profiting from technological innovation: implications for integration, collaboration, licensing and public policy. Research Policy, 15, 285-305.
    • TEECE, D. J., PISANO, G. & SHUEN, A. 1997. Dynamics Capabilities and Strategic Management. Strategic Management Journal, 18, 509-533.
    • TEICHER, B. A. & CHARI, R. V. 2011. Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res, 17, 6389-97.
    • THE GLOBE AND MAIL. 1994. International Company News: Sanofi to sell Sterling unit. The Globe and Mail, June 30, 1994
    • THE GUARDIAN. 1992. COMPASSIONATE USE' FOR NEW DRUG. The Guardian, October 22, 1992, p.Pg. 6.
    • THE INDEPENDENT. 1999. THE INVESTMENT COLUMN: CELLTECH LESSON. The Independent, May 18, 1999.
    • THE INSTITUTE OF CANCER RESEARCH. 2014. Discovering early chemotherapy drugs [Online]. UK: The Institute of Cancer Research (ICR). Available: http://www.icr.ac.uk/about-us/our-history/our-discoveries/we-discoveredchemotherapeutic-agents-which-are-still-in-use-more-than-50-years-later [Accessed October 15 2014].
    • THE WALL STREET TRANSCRIPT. 2001. Interview with Ian Miscampbell. July 11, 2001.
    • THOMKE, S. & KUEMMERLE, W. 2002. Asset Accumulation, Interdependence and Technological Change: Evidence from Pharmaceutical Drug Discovery. Strategic Management Journal, 23, 619-635.
    • THOMLINSON, R. H. & GRAY, L. H. 1955. The histological structure of some human lung cancers and the possible implications for radiotherapy. British Journal of Cancer, 9, 539-49.
    • THOMPSON, M. A., PRO, B., SARRIS, A., HAGEMEISTER, F. B., GOY, A., BLEYER, A., CABANILLAS, F. F., SAMANIEGO, F. & FAYAD, L. E. 2005. Results of a phase II study of 506U78 (Nelarabine) in refractory indolent B-cell or peripheral T-cell lymphoma. Blood, 106, 753A-753A.
    • THOMPSON, W. 2000. Couple pleads for public's help. Calgary Herald, February 19, 2000.
    • THOMSON FINANCIAL NEWS SUPER FOCUS. 2008. Glaxo's pazopanib shows promise in ovarian cancer. September 15, 2008.
    • TIDD, J. & BESSANT, J. 2013. Managing Innovation: Integrating Technological, Market and Organizational Change, Chichester, UK, John Wiley & Sons.
    • TIDD, J., BESSANT, J. & PAVITT, K. 1997. Managing Innovation, John Wiley & Sons.
    • TOBIAS, J. & HOCHHAUSER, D. 2014. Cancer and its Management. 7 ed. Hoboken: Wiley.
    • TOMISAWA, M., TOKUNAGA, T., OSHIKA, Y., TSUCHIDA, T., FUKUSHIMA, Y., SATO, H., KIJIMA, H., YAMAZAKI, H., UEYAMA, Y., TAMAOKI, N. & NAKAMURA, M. 1999. Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma. Eur J Cancer, 35, 133-7.
    • TOMLINSON, H. 2004. GSK speeds up cervical cancer vaccine race. The Guardian (London), October 29, 2004, p.Pg. 22.
    • TORONTO STAR. 2007. Five new cancer drugs to be released by 2010. The Toronto Star, June 19, 2007, p.Pg. B02.
    • TROWBRIDGE, I. S. & DOMINGO, D. L. 1981. ANTI-TRANSFERRIN RECEPTOR MONOCLONAL-ANTIBODY AND TOXIN-ANTIBODY CONJUGATES AFFECT GROWTH OF HUMAN-TUMOR CELLS. Nature, 294, 171-173.
    • TSUBOI, K., YOKOZAWA, T., SAKURA, T., WATANABE, T., FUJISAWA, S., YAMAUCHI, T., UIKE, N., ANDO, K., KIHARA, R., TOBINAI, K., ASOU, H., HOTTA, T. & MIYAWAKI, S. 2011. A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia. Leuk Res, 35, 1384-9.
    • UCHIDA, S., SHIMADA, Y., WATANABE, G., TANAKA, H., SHIBAGAKI, I., MIYAHARA, T., ISHIGAMI, S. & IMAMURA, M. 1998. In oesophageal squamous cell carcinoma vascular endothelial growth factor is associated with p53 mutation, advanced stage and poor prognosis. Br J Cancer, 77, 1704-9.
    • ULLRICH, A., COUSSENS, L., HAYFLICK, J. S., DULL, T. J., GRAY, A., TAM, A. W., LEE, J., YARDEN, Y., LIBERMANN, T. A., SCHLESSINGER, J., DOWNWARD, J., MAYES, E. L. V., WHITTLE, N., WATERFIELD, M. D. & SEEBURG, P. H. 1984. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature, 309, 418-425.
    • UNITED PRESS INTERNATIONAL 1996. Antibody may control breast cancer. United Press International. Los Angeles.
    • UNITED PRESS INTERNATIONAL. 1999. Cancer-boy set for drug trial test. United Press International, September 30, 1999.
    • UNIVERSITY OF CAMBRIDGE. 2009. Campath: from innovation to impact [Online]. Cambridge, UK. Available: http://www.cam.ac.uk/research/news/campath-frominnovation-to-impact [Accessed September 25, 2014 2014].
    • UPI 2005. Glaxo makes big foray into cancer market. UPI. New York, USA.
    • US FOOD AND DRUG ADMINISTRATION 2013. Paving the Way for Personalized Medicine: FDA's Role in a New Era of Medical Product Development In: FDA (ed.). USA.
    • UTKU, N. 2011 The End of Cytotoxics. European Oncology and Haematology, Touch Briefings 228-233.
    • VALIER, H. & TIMMERMANN, C. 2008. Clinical trials and the reorganization of medical research in post-Second World War Britain. Med Hist, 52, 493-510.
    • VAN DE VEN, A. H. 1986. CENTRAL PROBLEMS IN THE MANAGEMENT OF INNOVATION. Management Science, 32, 590-607.
    • VAN DER SCHOOT, C. E., VON DEM BORNE, A. E. & TETTEROO, P. A. 1987. Characterization of myeloid leukemia by monoclonal antibodies, with an emphasis on antibodies against myeloperoxidase. Acta Haematol, 78 Suppl 1, 32-40.
    • VAN LENTE, H. & RIP, A. 1998. The Rise of Membrane Technology: From Rhetorics to Social Reality. Social Studies of Science, 28, 221-254.
    • VAN WIJK, R., JANSEN, J. J. P. & LYLES, M. A. 2008. Inter- and Intra-Organizational Knowledge Transfer: A Meta-Analytic Review and Assessment of its Antecedents and Consequences. Journal of Management Studies, 45, 830-853.
    • VASELLA, D. & SLATER, R. 2003. Magic Cancer Bullet: How a Tiny Orange Pill Is Rewriting Medical History, New York, USA, HarperCollins Publishers.
    • VERTEX PHARMACEUTICALS. 2003. Vertex Pharmaceuticals Provides Corporate Update.
    • VITETTA, E. S., STONE, M., AMLOT, P., FAY, J., MAY, R., TILL, M., NEWMAN, J., CLARK, P., COLLINS, R., CUNNINGHAM, D. & ET AL. 1991. Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res, 51, 4052-8.
    • VOLIOTIS, D., MINEUR, P., DOMBRET, H., THEOBALD, M., BOOGAERTS, M., LOWENBERG, B., SIEVERS, E. L., LARSON, R. A., ESTEY, E., DIEHL, V. & STADTMAUER, E. A. 2000. The efficacy and safety of gemtuzumab ozogamicin (CMA-676) in patients with acute myeloid leukemia in first relapse. Annals of Oncology, 11, 95-95.
    • VOLM, M., KOOMAGI, R. & MATTERN, J. 1997a. Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer. Int J Cancer, 74, 64-8.
    • VOLM, M., KOOMAGI, R., MATTERN, J. & STAMMLER, G. 1997b. Angiogenic growth factors and their receptors in non-small cell lung carcinomas and their relationships to drug response in vitro. Anticancer Res, 17, 99-103.
    • VRAZO, F. 2006. Cancer Chronicles: On a mission for a drug. The Philadelphia Inquirer, May 1,2006.
    • WALDMANN, H., CLARK, M. R., WINTER, G. P. & RIECHMANN, L. 1998. Antibodies to the antigen campath-1. USA patent application US 08/235,705.
    • WALDMANN, H., CLARK, M. R., WINTER, G. P. & RIECHMANN, L. 2003. Antibodies to the antigen Campath-1. USA patent application US 08/407,620.
    • WALDMANN, H. & HALE, G. 2005. CAMPATH: from concept to clinic. Phil. Trans. R. Soc. B, 360, 1707-1711.
    • WALKER, G., KOGUT, B. & SHAN, W. 1997. Social Capital, Structural Holes and the Formation of an Industry Network. Organization Science, 8, 109-125.
    • WALKER, I. & NEWELL, H. 2009. Do molecularly targeted agents in oncology have reduced attrition rates? Nat Rev Drug Discov, 8, 15-16.
    • WALTER, A., PARBOTEEAH, K. P., RIESENHUBER, F. & HOEGL, M. 2011. Championship Behaviors and Innovations Success: An Empirical Investigation of University Spin-Offs*. Journal of Product Innovation Management, 28, 586-598.
    • WASHINGTON POST. 1988. Cancer Treatment. The Washington Post, December 16, 1988.
    • WEAVER, M. & LASKE, D. W. 2003. Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. Journal of Neuro-Oncology, 65, 3-13.
    • WEBSTER, A., MARTIN, P., LEWIS, G. & SMART, A. 2004. Integrating pharmacogenetics into society: in search of a model. Nat Rev Genet, 5, 663-669.
    • WEINBLATT, M. E., MADDISON, P. J., BULPITT, K. J., HAZLEMAN, B. L., UROWITZ, M. B., STURROCK, R. D., COBLYN, J. S., MAIER, A. L., SPREEN, W. R., MANNA, V. K. & JOHNSTON, J. M. 1995. CAMPATH-1H, A HUMANIZED MONOCLONAL-ANTIBODY, IN REFRACTORY RHEUMATOID-ARTHRITIS - AN INTRAVENOUS DOSE-ESCALATION STUDY. Arthritis and Rheumatism, 38, 1589-1594.
    • WELLCOME LIBRARY 2001a. Dr Howard J Schaeffer, Former VP Research, Development and Medical. In: COLLECTION, W. (ed.) Oral History of the Wellcome Foundation Ltd and Burroughs Wellcome Company: business. London: Wellcome Library.
    • WELLCOME LIBRARY 2001b. Fred A Coe, Former President & CEO Burroughs Wellcome & Co (USA) Inc. In: COLLECTION, W. (ed.) Oral History of the Wellcome Foundation Ltd and Burroughs Wellcome Company: business. London: Wellcome Library.
    • WELLCOME LIBRARY 2001c. Thomas Krenitsky, CEO Krenitsky Pharmaceuticals, Former VP Research 1989-1995. In: COLLECTION, W. (ed.) Oral History of the Wellcome Foundation Ltd and Burroughs Wellcome Company: business. London: Wellcome Library.
    • WELLCOME LIBRARY 2001d. William Sullivan, Former President & CEO BW USA. In: COLLECTION, W. (ed.) Oral History of the Wellcome Foundation Ltd and Burroughs Wellcome Company: business. London: Wellcome Library.
    • WELLMAN-LABADIE, O. & ZHOU, Y. 2010. The US Orphan Drug Act: Rare disease research stimulator or commercial opportunity? Health Policy, 95, 216-228.
    • WESTERMARK, K., HOLM, B. B., SODERHOLM, M., LLINARES-GARCIA, J., RIVIERE, F., AARUM, S., BUTLEN-DUCUING, F., TSIGKOS, S., WILK-KACHLICKA, A., N'DIAMOI, C., BORVENDEG, J., LYONS, D., SEPODES, B., BLOECHL-DAUM, B., LHOIR, A., TODOROVA, M., KKOLOS, I., KUBACKOVA, K., BOSCHTRABERG, H., TILLMANN, V., SAANO, V., HERON, E., ELBERS, R., SIOUTI, M., EGGENHOFER, J., SALMON, P., CLEMENTI, M., KRIEVINS, D., MATULEVICIENE, A., METZ, H., VINCENTI, A. C., VOORDOUW, A., DEMBOWSKA-BAGINSKA, B., NUNES, A. C., SALEH, F. M., FOLTANOVA, T., MOZINA, M., TORRENT I FARNELL, J., BEERMAN, B., MARIZ, S., EVERS, M. P., GREENE, L., THORSTEINSSON, S., GRAMSTAD, L., MAVRIS, M., BIGNAMI, F., LORENCE, A., BELORGEY, C., COMMITTEE FOR ORPHAN MEDICINAL, P. & THE EUROPEAN, M. 2011. European regulation on orphan medicinal products: 10 years of experience and future perspectives. Nat Rev Drug Discov, 10, 341-9.
    • WHEELER, C., STEPHENS, T., BYTH, K., GREEN, T., WEDGE, S., BLAKEY, D. & HUGHES, A. 2003. Novel approaches in oncology at AstraZeneca. European Journal of Cancer Supplements, 1, 3-8.
    • WHITTAKER, E. & BOWER, D. J. 1994. A shift to external alliances for product development in the pharmaceutical industry. R&D Management, 24, 249-260.
    • WILKINSON, R. W., ODEDRA, R., HEATON, S. P., WEDGE, S. R., KEEN, N. J., CRAFTER, C., FOSTER, J. R., BRADY, M. C., BIGLEY, A., BROWN, E., BYTH, K. F., BARRASS, N. C., MUNDT, K. E., FOOTE, K. M., HERON, N. M., JUNG, F. H., MORTLOCK, A. A., BOYLE, F. T. & GREEN, S. 2007. AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clinical Cancer Research, 13, 3682-3688.
    • WOLL, P. J., CROWTHER, D., JOHNSON, P. W. M., SOUKOP, M., HARPER, P. G., HARRIS, M., BRAMPTON, M. H. & NEWLANDS, E. S. 1995. PHASE-II TRIAL OF TEMOZOLOMIDE IN LOW-GRADE NON-HODGKINS-LYMPHOMA. British Journal of Cancer, 72, 183-184.
    • WONG, R., CHAU, I. & CUNNINGHAM, D. 2009. Gastrointestinal Cancer. In: CAVALLI, F., KAYE, S. B., HANSEN, H. H., ARMITAGE, J. O. & PICCART-GEBHART, M. J. (eds.) Textbook of Medical Oncology. Fourth Edition ed. London, UK: Informa UK.
    • WOODCOCK, J. & WOOSLEY, R. 2008 The FDA Critical Path Initiative and Its Influence on New Drug Development. Annual Review of Medicine, 59, 1-12
    • WORKMAN, P. & COLLINS, I. 2008. Chapter 1 - Modern cancer drug discovery: Integrating targets, technologies and treatments. In: NEIDLE, S. (ed.) Cancer Drug Design and Discovery. New York: Academic Press.
    • WORKMAN, P., MORGAN, J. E., TALBOT, K., WRIGHT, K. A., DONALDSON, J. & TWENTYMAN, P. R. 1986. CB 1954 revisited. II. Toxicity and antitumour activity. Cancer Chemother Pharmacol, 16, 9-14.
    • WORLD HEALTH ORGANISATION (WHO). 2014. Cancer [Online]. World Health Organisation (WHO). Available: http://www.who.int/mediacentre/factsheets/fs297/en/ [Accessed October 15 2014].
    • WRIGHT, P. 1988. Double boost for cancer battle. The Times, December 16, 1988.
    • WRIGHT, P. 1990. The mission to find a killer for cancer. The Times March 29, 1990.
    • WUYTS, S., STREMERSCH, S. & DUTTA, S. 2004. Portfolios of Interfirm Agreements in Technology-Intensive Markets: Consequences for Innovation and Profitability. Journal of Marketing, 68, 88-100.
    • XENOVA GROUP PLC 2003a. Annual Report.
    • XENOVA GROUP PLC. 2003b. Xenova Group plc: Offer for KS Biomedix Holdings plc. Press Release, August 14, 2003.
    • XENOVA GROUP PLC. 2003c. Xenova Group plc: Third Quarter Results. November 6, 2003.
    • XENOVA GROUP PLC. 2004a. Xenova and FDA reach agreement on PA Phase III trial programme for TransMID (TM). Press Release, May 11, 2004.
    • XENOVA GROUP PLC. 2004b. Xenova Group plc: Canadian Manufacturing Facility Sale Completes Planned Disposals. Press Release, September 3, 2004.
    • XENOVA GROUP PLC. 2004c. Xenova Group plc: TransMID (TM) - First Patient Treated in Pivotal Phase III GBM Trial. Press Release, July 7, 2004.
    • XENOVA GROUP PLC. 2005. Xenova Grants Licence to PharmaEngine for TransMID (TM) in China and South Korea. April 13, 2005.
    • YAMAMOTO, S., KONISHI, I., MANDAI, M., KURODA, H., KOMATSU, T., NANBU, K., SAKAHARA, H. & MORI, T. 1997. Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br J Cancer, 76, 1221- 7.
    • YAMASAKI, S. & RIHOUX, B. 2009. A Commented Review of Applications. In: RIHOUX, B. & RAGIN, C. C. (eds.) Configurational Comparative Methods: Qualitative Comparative Analysis (QCA) and Related Techniques. SAGE Publications.
    • YAQUB, O. 2008. Knowledge Accumulation and Vaccine Innovation: Lessons from Polio and HIV/AIDS. DPhil, University of Sussex
    • YAQUB, O. & NIGHTINGALE, P. 2012. Vaccine innovation, translational research and the management of knowledge accumulation. Social Science & Medicine, 75, 2143-2150.
    • YIN, R. K. 2009. Case Study Research: Design and Methods, Los Angeles, CA, Sage.
    • YOSHIJI, H., GOMEZ, D. E., SHIBUYA, M. & THORGEIRSSON, U. P. 1996. Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res, 56, 2013-6.
    • YUNG, W. K. A., PRADOS, M. D., YAYA-TUR, R., ROSENFELD, S. S., BRADA, M., FRIEDMAN, H. S., ALBRIGHT, R., OLSON, J., CHANG, S. M., O'NEILL, A. M., FRIEDMAN, A. H., BRUNER, J., YUE, N., DUGAN, M., ZAKNOEN, S., LEVIN, V. A. & TEMODAL BRAIN TUMOR, G. 1999. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Journal of Clinical Oncology, 17, 2762-2771.
    • ZEHR, L. 2001. KS Biomedix boosts reach with purchase of Avicenna. The Globe and Mail, July 14, 2001
    • ZENECA GROUP 1995. Zeneca Group boosts stake in SUGEN, Inc. Business Wire.
    • ZHANG, J., BADEN-FULLER, C. & MANGEMATIN, V. 2007. Technological knowledge base, R&D organization structure and alliance formation: Evidence from the biopharmaceutical industry. Research Policy, 36, 515-528.
    • ZHANG, J., YANG, P. L. & GRAY, N. S. 2009. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer, 9, 28-39.
  • No related research data.
  • No similar publications.

Share - Bookmark

Download from

Cite this article